News

Positive Data Reported for Monoclonal Antibody Treatment

Positive Data Reported for Monoclonal Antibody Treatment

Humanigen has reported positive data from the first clinical use of lenzilumab, which is a humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, in 12 COVID-19 patients. Those treated with the drug fully recovered in 5 days. Yourway has been working throughout the pandemic to transport clinical trial materials to patients that need it, despite challenges involving border closure and supply chain disruptions.

Back to Index
Media

Upcoming Event

Clinical Operations in Oncology Trials East Coast 2020

July 15-16, 2020
Boston, MA, USA (Virtual)

Media

Articles

SUPPLY CHAIN SOLUTIONS – Storage and Distribution Support for Clinical Trials Worldwide

Open chat
Come chat with us!
Hello! How can I help you?